Pfizer Boasts of ‘Blockbuster’ Profits from Treating Turbo Cancer Surge

Pfizer CEO Albert Bourla has gloated that his pharmaceutical company is expecting to reap “blockbuster” profits from treating the global surge in turbo cancers among the Covid-vaccinated.

Since Covid mRNA shots were rolled out to the public in early 2021, cases of rapidly developing cancers in young, healthy people have skyrocketed.

Oncologists and leading doctors around the world have been raising the alarm about the issue.

Many are reporting that patients who appear healthy are often dead within a week of being diagnosed.

The rapid onset of the disease has led to experts dubbing the phenomenon “turbo cancer.”

Evidence has continued to mount to suggest that the global turbo cancer epidemic is directly linked to Covid mRNA shots.

Many scientists have pointed to the DNA fragment contamination in the injections as the cause of the cancers.

However, the devastating impact is not bad news for everyone, apparently.

According to Pfizer CEO Albert Bourla, skyrocketing cancer cases present an opportunity to make “blockbuster” profits.

Celebrating these new opportunities, Bourla gloated that cancer “is our new Covid.”

The Big Pharma boss made the claims during a new interview with Fox Business where he discussed Pfizer’s recent acquisition of cancer treatment company Seagen.

The company expects to score big on cancer drugs, Bourla said, as the pharma giant seeks to reverse its post-Covid business decline.

The pandemic brought record revenue to the company.

Slay the latest News for free!

We don’t spam! Read our privacy policy for more info.

In 2022 alone, Pfizer’s total sales amounted to $157 billion, with its Covid vaccine accounting for $37.8 billion and its antiviral treatment pill, Paxlovid, bringing in another $18.9 billion.

In 2023, sales were down by more than half and accounted for $71 billion.

The company’s shares have fallen by 42% since the end of 2022 amid the rapid decline in demand for its Covid-related products.

This led to a major cost-cutting campaign, including hundreds of layoffs at Pfizer’s UK, US, and Irish facilities.

In his interview with Fox Business, Bourla praised the measures as a “very good cost containment” campaign, crediting it for the “very good results” his company showed in early 2024.

Pfizer is also on the verge of striking gold again with its new strategy, he boasted.

“Oncology, it is our new Covid,” the Pfizer CEO said.

“We did what we did with Covid.

“We are very proud to have saved the world but it is behind us now.

“We want to do [it] once more and I think oncology is our best chance to do it.”

WATCH:

 

In late 2023, Pfizer completed the $43 billion acquisition of Seagen, formerly Seattle Genetics.

Seagen is a biotechnology company specializing in monoclonal antibody-based drugs, also known as antibody-drug conjugates or ADCs.

They are designed to kill tumor cells while leaving healthy tissues relatively unaffected.

Seagen was previously known for its flagship product Adcetris, which is used to treat lymphoma and Hodgkin’s lymphoma.

According to drugs.com, the medicine costs around $11.91 for a 50-mg dose.

Another drug in the company’s portfolio that has demonstrated “phenomenal performance” is Padcev, according to Bourla.

Padcev is used to treat bladder cancer, and its sales have “had a growth of 164%” since the US pharma giant acquired it, he said.

The average price for Padcev is $4,446 per 30-mg dose, according to drugs.com.

“That demonstrates how well we’ve invested the money,” Bourla said, commenting on Padcev’s performance.

He also promised blockbuster drugs in the future that “will have a significant impact on cancer patients.”

Pfizer announced its shift toward cancer treatment in late 2023.

“Nothing scares people all over the world more than cancer, because it affects everyone,” Bourla said at the time.

“I hope we will be successful in our mission,” he added.

“I am optimistic that in the next 10 years, we will see significant advancement.”

In January 2024, the company said it plans to have at least eight cancer treatment drugs by 2030 and double the number of patients treated with its innovative medicines, up from 2.3 million in 2023.

The comments from Bourla come as world-renowned experts continue to speak out about a looming “wave” of cancer and heart failure-related deaths among the vaxxed.

As Slay News reported, Bill Gates’s former vaccine specialist has blown the whistle to warn of a coming “wave of morbidity” and “mortality” among the Covid mRNA vaccinated.

Former Bill & Melinda Gates Foundation scientist and vaccine expert Dr. Geert Vanden Bossche has warned that populations around the world will soon experience a “completely unprecedented” plunge.

Bossche predicts that the death toll will be “up to 30-40% in highly vaccinated countries.”

Additionally, Professor Dolores Cahill, a world-renowned immunology expert, issued an explosive warning to the public that everyone who has been vaccinated with Covid mRNA shots “will die within 3 to 5 years, even if they have had only one injection.”

Cahill explains how mRNA in the injections harms all recipients and acts like a ticking time bomb in the Covid-vaccinated.

READ MORE – Renowned Scientist: All Covid-Vaxxed ‘Will Die in 3 to 5 Years’

SHARE:
join telegram

READERS' POLL

Who is the best president?

By completing this poll, you gain access to our free newsletter. Unsubscribe at any time.

By Frank Bergman

Frank Bergman is a political/economic journalist living on the east coast. Aside from news reporting, Bergman also conducts interviews with researchers and material experts and investigates influential individuals and organizations in the sociopolitical world.

Subscribe
Notify of

Recommended

15
0
Would love your thoughts, please comment.x
()
x